Efficacy and Safety of Chinese Herbal Medicine in Patients with Acute Intracerebral Hemorrhage: Protocol for a Randomized Placebo-Controlled Double-Blinded Multicenter Trial.

Journal: Cerebrovascular diseases (Basel, Switzerland)
PMID:

Abstract

INTRODUCTION: The popular traditional Chinese medicine (TCM) compound FYTF-919 (Zhong Feng Xing Nao prescription) may improve outcome from acute intracerebral hemorrhage (ICH) through effects on brain edema, hematoma absorption, and the immune system. This study is to assess whether FYTF-919 is safe and effective as compared to matching placebo treatment in patients with acute ICH.

Authors

  • Yang Zhao
    The George Institute for Global Health, Faculty of Medicine, University of New South Wales, Sydney, NSW, Australia.
  • Wanzhen Cui
    The Second Clinical Medical School, Guangzhou University of Chinese Medicine, Guangzhou, China, wanzhencc@163.com.
  • Tingting Xie
    Neurology Department, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China.
  • Kai Zhao
    Department of Gastroenterology, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
  • Yunke Li
    The George Institute for Global Health China, Beijing, China.
  • Yingfeng Wan
    Department of Neurosurgery, Medical School, University of Michigan, Detroit, Michigan, USA.
  • Xia Wang
    Department of Neurology, The Sixth People's Hospital of Huizhou City, Huizhou, China.
  • Qiang Li
    Department of Dermatology, Air Force Medical Center, PLA, Beijing, People's Republic of China.
  • Chen Xiaoying
    The George Institute for Global Health, University of New South Wales, Sydney, New South Wales, Australia.
  • Zhenchuan Liu
    Department of Neurological Intensive Care Unit, Linyi People's Hospital, Linyi, China.
  • Haining Zhao
    The Second Clinical Medical School, Guangzhou University of Chinese Medicine, Guangzhou, China.
  • Baoying Gong
    The Second Clinical Medical School, Guangzhou University of Chinese Medicine, Guangzhou, China.
  • Ruihua Wang
    Neurology Department, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China.
  • Manli Wu
    The Second Clinical Medical School, Guangzhou University of Chinese Medicine, Guangzhou, China.
  • Dou Wang
    The Second Clinical Medical School, Guangzhou University of Chinese Medicine, Guangzhou, China.
  • Yanwen Zheng
    The Second Clinical Medical School, Guangzhou University of Chinese Medicine, Guangzhou, China.
  • Yanjia Chen
    The College of Basic Medical Sciences, Guangzhou University of Chinese Medicine, Guangzhou, China.
  • Yue Chen
    The College of Basic Medical Sciences, Guangzhou University of Chinese Medicine, Guangzhou, China.
  • Qihua Guo
    Department of Traditional Chinese Medicine, Zhongshan City People's Hospital, Zhongshan, China.
  • Changlian Gan
    School of Pharmaceutical Science, Guangzhou University of Chinese Medicine, Guangzhou, China.
  • Fengyuan Che
    Department of Neurology, Linyi People's Hospital, Linyi, China.
  • Lili Song
    The George Institute for Global Health, Faculty of Medicine, University of New South Wales, Sydney, NSW, Australia.
  • Craig S Anderson
    The George Institute for Global Health, Faculty of Medicine, University of New South Wales, Sydney, NSW, Australia.
  • Jianwen Guo
    Neurology Department, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China.